Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has received a Rectification Order from the Assistant Commissioner of Income Tax, Central Circle 3, Thane, rectifying the error in tax computation and dropping the tax demand of Rs. 161.92 Crores raised pursuant to the Demand Notice received on March 17, 2026.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has published a newspaper advertisement regarding the completion of dispatch of 9th AGM Notice and Annual Report, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has released its Business Responsibility and Sustainability Report for the financial year 2025-26, as per SEBI regulations.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has announced its Annual Report for the financial year ended March 31, 2026, and has scheduled its Ninth Annual General Meeting (AGM) to be held on September 18, 2026, through Video Conference (VC) / Other Audio-Visual Means (OAVM).

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has announced the dispatch of Notice of Ninth Annual General Meeting (AGM) scheduled to be held on September 18, 2026, to consider and adopt the Audited Standalone Financial Statements for the financial year ended March 31, 2026, and other business.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has informed the stock exchange regarding the Newspaper publication with respect to the Ninth Annual General Meeting.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has converted partly paid-up Rights Equity Shares into fully paid-up equity shares as part of its rights issue. The company has received the necessary call monies from shareholders, allowing it to proceed with the conversion. The converted shares will be listed and traded accordingly.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has informed the Exchange regarding allotment of 2250 equity shares pursuant to exercise of ESOP options.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has updated its announcement regarding the appointment of Chief Information Officer (CIO) and Senior Management Personnel (SMP) of the company. The effective date of Mr. Ajit Manocha's appointment has been revised from August 10, 2026 to August 17, 2026 due to personal reasons.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd reported Q1 FY27 financial results, with revenues at INR384 crores, up 20% year-on-year, EBITDA at INR63.5 crores, up 10% year-on-year, and PAT at INR16.3 crores, up 55% year-on-year.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has published unaudited financial results for the quarter ended June 30, 2026, through a newspaper advertisement and on its website.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has submitted the Machine Readable copy of Financial results for the quarter ended June 30, 2026, as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has uploaded the audio recording of its Q1 FY27 earnings call held on July 23, 2026, for the quarter ended June 30, 2026, on its website.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, confirming that there has been no deviation in the utilization of the proceeds of the Rights Issue.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has informed the exchange that there is no deviation or variation in the use of proceeds raised through its Rights Issue for the quarter ended June 30, 2026.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has informed the Exchange regarding allotment of 2250 Equity Shares pursuant to exercise of ESOP options.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has appointed Mr. Ajit Manocha as Chief Information Officer (CIO) with effect from August 10, 2026, as part of the Senior Management Personnel (SMP) of the company.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd reported strong Q1'27 base business performance with continued growth and profitability. The company's base business revenues stood at INR 3,077 Mn, up 24% YoY, and EBITDA at INR 722 Mn, up 8% YoY, despite input cost pressures resulting from ongoing geopolitical developments in West Asia. The company's overall revenues stood at INR 3,843 Mn, up 20% YoY, and EBITDA at INR 635 Mn, up 10% YoY, and PAT at INR 163 Mn, up 55% YoY, marking the highest EBITDA and PAT reported over the last eighteen quarters.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd reported strong Q1'27 base business performance with continued growth and profitability. The company's base business revenues stood at INR 3,077 Mn, up 24% YoY, with EBITDA at INR 722 Mn, up 8% YoY. The company's overall revenues stood at INR 3,843 Mn, up 20% YoY, with EBITDA at INR 635 Mn, up 10% YoY, and PAT at INR 163 Mn, up 55% YoY.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the board of directors approving the results and a limited review report from Deloitte Haskins & Sells.